Study shows ursodeoxycholic acid therapy holds promise

Published: 2011-01-17 06:57:00

Updated: 2011-01-17 06:57:00

High-dose ursodeoxycholic acid (UDCA) therapy, an active ingredient of Ursa, has shown promising results for its safety and tolerability in the treatment of nonalcoholic steatohepatitis (NASH), according to Daewoong Pharma.

In a 12-month study published by peer-view journal, Journal of Hepato...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK